Heat shock protein 90 inhibitor RGRN-305 potently attenuates skin inflammation.

ABSTRACT:

Introduction

Chronic inflammatory skin diseases may have a profound negative impact on the quality of life. Current treatment options may be inadequate, offering an unsatisfactory response or side effects. Therefore, ongoing efforts exist to identify novel effective and safe treatments. Heat shock protein (HSP) 90 is a chaperone that promotes the activity of a wide range of client proteins including key proinflammatory molecules involved in aberrant inflammation. Recently, a proof-of-concept clinical trial of 13 patients suggested that RGRN-305 (an HSP90 inhibitor) may be an oral treatment for psoriasis. However, HSP90 inhibition may be a novel therapeutic approach extending beyond psoriasis to include multiple immune-mediated inflammatory skin diseases.

Methods

This study a

SUBMITTER: Ben Abdallah H 

PROVIDER: S-EPMC9941631 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature